Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LACTEOL 340 mg for diarrhea-predominant irritable bowel syndrome (pilot study)
2009-017874-20Phase 3Completed
- Sponsor
- Axcan Pharma Inc.
- Start
- Feb 2010
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Lactobacillus LB in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Axcan Pharma Inc. Primary endpoint: Subject global assessment of relief (SGA) responder rate. Started Feb 2010; status: completed.
02
Drugs
Lactobacillus LB
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2009-017874-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017874-20.